Blume Capital Management’s QIAGEN NV QGENF Stock Holding History

Blume Capital Management’s Portfolio QGENF Stock Details QGENF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-124	Closed	-$3K	–	228
2016 Q4	$3K	Hold	124	–	–	﹤0.01%	196
2016 Q3	$3K	Hold	124	–	–	﹤0.01%	186
2016 Q2	$3K	Hold	124	–	–	﹤0.01%	202
2016 Q1	$3K	Hold	124	–	–	﹤0.01%	231
2015 Q4	$3K	Hold	124	–	–	﹤0.01%	230
2015 Q3	$3K	Hold	124	–	–	﹤0.01%	231
2015 Q2	$3K	Hold	124	–	–	﹤0.01%	229
2015 Q1	$3K	Hold	124	–	–	﹤0.01%	269
2014 Q4	$3K	Hold	124	–	–	﹤0.01%	280
2014 Q3	$3K	Hold	124	–	–	﹤0.01%	185
2014 Q2	$3K	Hold	124	–	–	﹤0.01%	203
2014 Q1	$3K	Hold	124	–	–	﹤0.01%	225
2013 Q4	$3K	Buy	+124	New	+$3K	﹤0.01%	248

Other funds holding QGENF

BJCM

Blue Jay Capital Management Los Angeles, California $147M AUM 64.18% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital Fund Management (CFM) Paris, France $22.1B AUM 20.49% 1-Year Est. Return

Twin Tree Management Dallas, Texas $4.75B AUM 58.16% 1-Year Est. Return

Blume Capital Management's QGENF Position: Q1 2017 in Review

Blume Capital Management sold out of QIAGEN NV (QGENF) in Q1 2017, closing a stake of 124 shares — an estimated $3K sold.

Blume Capital Management first reported a position in QGENF in Q4 2013 and held it in 13 quarters. The position peaked at $3K in Q4 2016. 6 funds tracked by Wall St. Rank hold QGENF as of Q1 2017.

Blume Capital Management reported no remaining QIAGEN NV position as of Q1 2017 after selling out during the quarter.
Blume Capital Management sold 124 QIAGEN NV shares in Q1 2017, an estimated $3K.
Blume Capital Management first reported a position in QIAGEN NV in Q4 2013 and held it in 13 quarters.
Blume Capital Management's QIAGEN NV position peaked at $3K in Q4 2016.
6 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2017.

Based on Blume Capital Management's 13F filing for Q1 2017, filed 12 May 2017.